BURROUGHS WELLCOME TO RELAUNCH ANTIDEPRESSANT WELLBUTRIN IN MID-JULY AFTER ABORTED LAUNCH IN 1986; FDA-APPROVED LABELING INCLUDES DATA ON SEIZURE RISK